GlassScriptPhysician profile
Robin Marie Reid
NPI 1356583355
$476.41
in general payments reported to CMS, 2019-2025
11 companies · $92.86 in 2025
The $92.86 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $44.20 · 2022: $57.22 · 2023: $40.82 · 2024: $62.08 · 2025: $92.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.10 | 2019-2025 | Krazati |
| Janssen Biotech, INC. | $86.30 | 2019-2025 | Rybrevant, Darzalex |
| Genzyme Corporation | $62.08 | 2024 | |
| Celgene Corporation | $61.22 | 2019-2022 | |
| Amgen INC. | $48.36 | 2019 | |
| Glaxosmithkline, LLC. | $26.34 | 2025 | Ojjaara |
| Daiichi Sankyo INC. | $20.64 | 2023 | Enhertu |
| Merck Sharp & Dohme LLC | $19.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.50 | 2025 | Tagrisso |
| Astellas Pharma US INC | $16.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.